NR3C1 and cancer: In conclusion, we report the novel SEGRA 4-(1-hydroxy-2-(piperidin-1-yl)ethyl)phenol (CpdA-03), possessing the therapeutic anti-cancer potential of GCs, and more importantly, of the parent compound CpdA, while lacking GR TA activity that causes side effects and therapy resistance.